Related Experiment Video
Updated: Feb 6, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy
Jefferson Loso1, Natalie Lund1, Maxim Avanesov2
1Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany.
Insights
Fabry disease (FD) patients show elevated MMP-9 and angiostatin, indicating increased extracellular matrix turnover. Endothelial dysfunction, marked by altered symmetric dimethylarginine (SDMA) and hArg/SDMA ratios, may contribute to Fabry cardiomyopathy (FC).
Area of Science:
- Biochemistry
- Cardiology
- Genetics
Background:
- Fabry disease (FD) is characterized by vasculopathy and endothelial dysfunction, but their role in cardiac manifestation (Fabry cardiomyopathy, FC) is unclear.
- FC is the primary cause of mortality in FD, necessitating a deeper understanding of its pathological mechanisms.
Purpose of the Study:
- To investigate the pathological mechanisms underlying cardiac manifestations in Fabry disease.
- To explore the role of endothelial dysfunction and extracellular matrix turnover in Fabry cardiomyopathy.
Main Methods:
- Serum samples from 17 healthy controls and 22 FD patients (15 with FC, 7 without) were analyzed.
- Cardiac magnetic resonance imaging defined FC (LV wall thickening >12 mm).
- Multiplex ELISA assays measured 23 angiogenesis markers, while specific assays quantified L-homoarginine (hArg), L-arginine, ADMA, and symmetric Dimethylarginine (SDMA) using LC-MS.
Main Results:
- Angiostatin and matrix metalloproteinase 9 (MMP-9) were elevated in FD patients irrespective of FC.
- Symmetric Dimethylarginine (SDMA) concentrations were significantly higher in patients with FC and correlated with LV mass, hsT, and lyso-Gb3.
- The hArg/SDMA ratio was lowest in FC patients, and a link between kidney and cardiac function was observed.
Conclusions:
- Elevated MMP-9 and angiostatin suggest increased extracellular matrix turnover in Fabry disease.
- Altered SDMA and hArg/SDMA ratios indicate that endothelial dysfunction may contribute to Fabry cardiomyopathy.
- Findings highlight potential mechanisms linking systemic disease processes to cardiac involvement in Fabry disease.
Abstract:
Background: Fabry disease (FD) is characterized by early development of vasculopathy and endothelial dysfunction. However, it is unclear whether these findings also play a pivotal role in cardiac manifestation. As Fabry cardiomyopathy (FC) is the leading cause of death in FD, we aimed to gather a better insight in pathological mechanisms of the disease. Methods: Serum samples were obtained from 17 healthy controls, 15 FD patients with and 7 without FC. FC was defined by LV wall thickening of >12 mm in cardiac magnetic resonance imaging and serum level of proBNP, high sensitive Troponin T (hsT), and globotriaosylsphingosine (lyso-GB3) were obtained. A multiplex ELISA-Assay for 23 different angiogenesis markers was performed in pooled samples. Markers showing significant differences among groups were further analyzed in single samples using specific Elisa antibody assays. L-homoarginine (hArg), L-arginine, asymmetric (ADMA), and symmetric Dimethylarginine (SDMA) were quantified by liquid chromatography-mass spectrometry. Results: Angiostatin and matrix metalloproteinase 9 (MMP-9) were elevated in FD patients compared to controls independently of the presence of FC (angiostatin: 98 ± 25 vs. 75 ± 15 ng/mL; p = 0.001; MMP-9: 8.0 ± 3.4 vs. 5.0 ± 2.4 μg/mL; p = 0.002). SDMA concentrations were highest in patients with FC (0.90 ± 0.64 μmol/l) compared to patients without (0.57 ± 0.10 μmol/l; p = 0.027) and vs. controls (0.58 ± 0.12 μmol/l; p = 0.006) and was positively correlated with indexed LV-mass (r = 0.61; p = 0.003), hsT (r = 0.56, p = 0.008), and lyso-Gb3 (r = 0.53, p = 0.013). Accordingly, the ratio of L-homoarginine to SDMA (hArg/SDMA) was lowest in patients with FC (2.63 ± 1.78) compared to controls (4.16 ± 1.44; p = 0.005). For L-arginine, hArg and ADMA no significant differences among groups could be detected, although a trend toward higher ADMA and lower hArg levels could be observed in the FC group. Furthermore, a significant relationship between kidney and cardiac function could be revealed (p = 0.045). Conclusion: Elevated MMP-9 and angiostatin levels suggest an increased extracellular matrix turnover in FD patients. Furthermore, endothelial dysfunction may also be involved in FC, as SDMA and hArg/SDMA are altered in these patients.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy VI: Nursing Management

